National Cancer Institute (NCI) shared on X:
“In a Clinical Trial, an injectable form of nivolumab (Opdivo) was as effective against kidney cancer as the intravenous form of the drug. Side effects were also similar, and treatment time was shorter.”
National Cancer Institute (NCI) shared on X:
“In a Clinical Trial, an injectable form of nivolumab (Opdivo) was as effective against kidney cancer as the intravenous form of the drug. Side effects were also similar, and treatment time was shorter.”